N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: Potential for cancer therapy

Oncogene

Volumn 32, Issue 7, 2013, Pages 920-929

  Ruhul Amin, A R M ^a,b   Thakur, V S ^a   Gupta, K ^a   Agarwal, M K ^c   Wald, D N ^a   Shin, D M ^b   Agarwal, M L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Invenio Therapeutics   (United States)

Author keywords

apoptosis; aspartate transcarbamylase inhibitor; DNA damage; p53 family; replicative stress; signal transduction

Indexed keywords

BIM PROTEIN; PROTEIN BCL 2; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; PROTEIN P73; SMALL INTERFERING RNA; SPARFOSIC ACID; TAP73 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROTECTION; GENE OVEREXPRESSION; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASPARTIC ACID; CELLS, CULTURED; DNA-BINDING PROTEINS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHONOACETIC ACID; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84874110335     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.96     Document Type: Article

References (79)

1. Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 2010; 396: 85-89.
2. Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2010; 2: a001040.
3. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1: a001883.
4. Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol 2010; 2: a000919.
5. Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5: 251-265.
6. Chung J, Irwin MS. Targeting the p53-family in cancer and chemosensitivity: triple threat. Curr Drug Targets 2010; 11: 667-681.
7. Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009; 27: 2712-2725.
8. Wiman KG. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010; 29: 4245-4252.
9. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998; 273: 1-4.
10. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.
11. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, deathinducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316.
12. Amin AR, Paul RK, Thakur VS, Agarwal ML. A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. Cancer Res 2007; 67: 5617-5621.
13. Amin AR, Thakur VS, Paul RK, Feng GS, Qu CK, Mukhtar H et al. SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. Proc Natl Acad Sci USA 2007; 104: 5419-5424.
14. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV et al. p73 in Cancer. Genes Cancer 2011; 2: 491-502.
15. John K, Alla V, Meier C, Putzer BM. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ 2011; 18: 874-886.
16. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
17. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 2003; 28: 663-670.
18. Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M, Bonati A. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res 2009; 15: 6495-6502.
19. Dotsch V, Bernassola F, Coutandin D, Candi E, Melino G. p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol 2010; 2: a004887.
20. Ichimiya S, Nimura Y, Kageyama H, Takada N, Sunahara M, Shishikura T et al. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 1999; 18: 1061-1066.
21. Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G et al. DeltaNp73alpha accumulates in human neuroblastic tumors. Am J Pathol 2002; 160: 631-639.
22. Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006; 24: 805-815.
23. Zaika AI, Kovalev S, Marchenko ND, Moll UM. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 1999; 59: 3257-3263.
24. Ng SW, Yiu GK, Liu Y, Huang LW, Palnati M, Jun SH et al. Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 2000; 19: 1885-1890.
25. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 1999; 91: 1154-1158.
26. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 1998; 9: 897-903.
27. Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 1999; 18: 1629-1633.
28. Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L et al. Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 1999; 39: 94-100.
29. Sunahara M, Ichimiya S, Nimura Y, Takada N, Sakiyama S, Sato Y et al. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int J Oncol 1998; 13: 319-323.
30. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 2007; 98: 392-400.
31. Malaguarnera R, Vella V, Vigneri R, Frasca F. p53 family proteins in thyroid cancer. Endocr Relat Cancer 2007; 14: 43-60.
32. Leupin N, Luthi A, Novak U, Grob TJ, Hugli B, Graber H et al. P73 status in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2004; 45: 1205-1207.
33. Tschan MP, Grob TJ, Peters UR, Laurenzi VD, Huegli B, Kreuzer KA et al. Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun 2000; 277: 62-65.
34. Faridoni-Laurens L, Tourpin S, Alsafadi S, Barrois M, Temam S, Janot F et al. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. Cell Cycle 2008; 7: 1587-1596.
35. Swyryd EA, Seaver SS, Stark GR. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture. J Biol Chem 1974; 249: 6945-6950.
36. Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR. A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci USA 1998; 95: 14775-14780.
37. Agarwal MK, Hastak K, Jackson MW, Breit SN, Stark GR, Agarwal ML. Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci USA 2006; 103: 16278-16283.
38. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-948.
39. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995; 92: 8493-8497.
40. Paulson TG, Almasan A, Brody LL, Wahl GM. Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol Cell Biol 1998; 18: 3089-3100.
41. Moffitt KL, Martin SL, Walker B. From sentencing to execution-the processes of apoptosis. J Pharm Pharmacol 2010; 62: 547-562.
42. Brenner D, Mak TW. Mitochondrial cell death effectors. Curr Opin Cell Biol 2009; 21: 871-877.
43. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
44. Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 2010; 9: 417-422.
45. Ghiotto F, Fais F, Bruno S. BH3-only proteins: the death-puppeteer's wires. Cytometry A 2010; 77: 11-21.
46. Lomonosova E, Chinnadurai G. BH3-only proteins in apoptosis and beyond: an overview. Oncogene 2008; 27(Suppl 1): S2-S19.
47. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
48. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998; 17: 384-395.
49. Li R, Moudgil T, Ross HJ, Hu HM. Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 2005; 12: 292-303.
50. Toh WH, Nam SY, Sabapathy K. An essential role for p73 in regulating mitotic cell death. Cell Death Differ 2010; 17: 787-800.
51. Busuttil V, Droin N, McCormick L, Bernassola F, Candi E, Melino G et al. NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proc Natl Acad Sci USA 2010; 107: 18061-18066.
52. Amin AR, Thakur VS, Gupta K, Jackson MW, Harada H, Agarwal MK et al. Restoration of p53 functions protects cells from concanavalin A-induced apoptosis. Mol Cancer Ther 2010; 9: 471-479.
53. Miyaguchi Y, Tsuchiya K, Sakamoto K. P53 negatively regulates the transcriptional activity of FOXO3a under oxidative stress. Cell Biol Int 2009; 33: 853-860.
54. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19: 1438-1449.
55. Amin AR, Wang D, Zhang H, Peng S, Shin HJ, Brandes JC et al. Enhanced antitumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem 2010; 285: 34557-34565.
56. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996; 10: 934-947.
57. Wadler S, Gleissner B, Hilgenfeld RU, Thiel E, Haynes H, Kaleya R et al. Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma. Eur J Cancer 1996; 32A: 1254-1256.
58. Redei I, Green F, Hoffman JP, Weiner LM, Scher R, O'Dwyer PJ. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer. Invest New Drugs 1994; 12: 319-321.
59. Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J et al. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma. Cancer Res 1993; 53: 4828-4836.
60. Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM et al. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res 2010; 70: 7155-7165.
61. Chakraborty J, Banerjee S, Ray P, Hossain DM, Bhattacharyya S, Adhikary A et al. Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells. J Biol Chem 2010; 285: 33104-33112.
62. Vilgelm A, El-Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat 2008; 11: 152-163.
63. Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci 2005; 96: 729-737.
64. Kirschnek S, Vier J, Gautam S, Frankenberg T, Rangelova S, Eitz-Ferrer P et al. Molecular analysis of neutrophil spontaneous apoptosis reveals a strong role for the pro-apoptotic BH3-only protein Noxa. Cell Death Differ 2011; 18: 1805-1814.
65. Santidrian AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias M et al. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood 2010; 116: 3023-3032.
66. Morales AA, Gutman D, Lee KP, Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 2008; 111: 5152-5162.
67. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
68. Hastak K, Paul RK, Agarwal MK, Thakur VS, Amin AR, Agrawal S et al. DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATRCHK1-dependent p53 activation. Proc Natl Acad Sci USA 2008; 105: 6314-6319.
69. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-809.
70. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814-817.
71. Gottifredi V, Karni-Schmidt O, Shieh SS, Prives C. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol Cell Biol 2001; 21: 1066-1076.
72. Lohr K, Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003; 278: 32507-32516.
73. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R et al. p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem 2004; 279: 50976-50985.
74. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V. DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur. Cell Death Differ 2004; 11: 685-687.
75. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R et al. Isoformspecific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2010; 24: 549-560.
76. Bischoff FZ, Strong LC, Yim SO, Pratt DR, Siciliano MJ, Giovanella BC et al. Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome. Oncogene 1991; 6: 183-186.
77. Hastak K, Agarwal MK, Mukhtar H, Agarwal ML. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005; 19: 789-791.
78. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000; 407: 645-648.
79. Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 1989; 49: 5167-5175.